Figure 1.

Murine FUTCs exhibit functional profiles comparable to conditionally reprogrammed cultures

(A) Schematic of comprehensive drug testing of KP and KL tumor-derived cultures to validate the ability of FUTCs to identify subtype-selective treatments.

(B) Viability assessment of FUTCs at 0 and 72 h.

(C–E) Dose-response curves of tumor-matched FUTCs and CR cultures treated for 72 h with (C) idasanutlin (MDM2 antagonist), or (D) tanespimycin (HSP90 inhibitor), or (E) gemcitabine (nucleoside analog).

(F) DSS calculated for (C)–(E) and compared between KL and KP subtypes for both FUTCs and CR cultures.

Data are represented as means ± SEMs. Student’s t test: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.